Кристи Фанк - Грудь. Руководство пользователя [litres]

A. C. Degnim et al., “Pseudoangiomatous Stromal Hyperplasia and Breast Cancer Risk,” Annals of Surgical Oncology 17, no. 12 (2010): 3269–3277.

E. E. Lower, H. H. Hawkins, and R. P. Baughman, “ Breast Disease in Sarcoidosis,” Sarcoidosis, Vasculitis, and Diffuse Lung Diseases: Official Journal of World Association of Sarcoidosis and Other Granulomatous Disorders 18, no. 3 (2001): 301–306.

P. P. Rosen, Breast Pathology , 3rd Edition (Philadelphia: Lippincott Williams & Wilkins, 2009). Глава девятая. «У вас рак». Что делать после постановки диагноза?

C. I. Li, D. J. Uribe, and J. R. Daling, “Clinical Characteristics of Different Histologic Types of Breast Cancer,” British Journal of Cancer 93, no. 9 (2005): 1046–1052.

M. E. Sanders et al., “Continued Observation of the Natural History of Low-Grade Ductal Carcinoma in Situ Reaffirms Proclivity for Local Recurrence Even after More than 30 Years of Follow Up,” Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology , Inc. 28, no. 5 (May 2015): 662–669.

S. A. Lari and H. M. Kuerer, “Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review,” Journal of Cancer 2 (2011): 232–261.

National Comprehensive Cancer Network, “NCCN Clinical Practice Guidelines in Oncology: Breast Cancer,” http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.

B. C. Pestalozzi et al., “Distinct Clinical and Prognostic Features of Infiltrating Lobular Carcinoma of the Breast: Combined Results of 15 International Breast Cancer Study Group Clinical Trials,” Journal of Clinical Oncology 26, no. 18 (2008): 3006–3014.

N. Wasif et al., “Invasive Lobular vs. Ductal Breast Cancer: A Stage-Matched Comparison of Outcomes,” Annals of Surgical Oncology 17, no. 7 (2010): 1862–1869; J. G. Molland et al., “Infiltrating Lobular Carcinoma – a Comparison of Diagnosis, Management and Outcome with Infiltrating Duct Carcinoma,” The Breast 13, no. 5 (2004): 389–396.

I. Jatoi et al., “Breast Cancer Adjuvant Therapy: Time to Consider Its Time Dependent Effects,” Journal of Clinical Oncology 29, no. 17 (2011): 2301–2304.

C. E. DeSantis et al., “Breast Cancer Statistics, 2015: Convergence of Incidence Rates Between Black and White Women.” CA: A Cancer Journal for Clinicians 66, no. 1 (2016): 31–42; B. A. Kohler et al., “Annual Report to the Nation on the Status of Cancer, 1975–2011: Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State,” Journal of the National Cancer Institute 107, no. 6 (2015): djv048; R. M. Amimi et al., “Traditional Breast Cancer Risk Factors in Relation to Molecular Subtypes of Breast Cancer,” Breast Cancer Research and Treatment 131 (2012): 159–167.

K. C. Aalders et al., “Characterisation of Multifocal Breast Cancer Using the 70-Gene Signature in Clinical Low-Risk Patients Enrolled in the EORTC 10041/BIG 03–04 MINDACT Trial,” European Journal of Cancer 79 (2017): 98–105; J. A. Sparano et al., “Prospective Validation of a 21-Gene Expression Assay in Breast Cancer,” New England Journal of Medicine 373, no. 21 (2015): 2005–2014.

J. Iqbal et al., “Differences in Breast Cancer Stage at Diagnosis and Cancer-Specific Survival by Race and Ethnicity in the United States,” Journal of the American Medical Association 313, no. 2 (2015): 165–173; “Breast Cancer Survival Rates,” American Cancer Society, последнее обновление 20 декабря 2017 года, http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-survival-by-stage.

A. M. Soto et al., “Does Breast Cancer Start in the Womb?” Basic and Clinical Pharmacology and Toxicology 102, no. 2 (2008): 125–133.

P. G. M. Peer et al., “Age-Dependent Growth Rate of Primary Breast Cancer,” Cancer 71 (1993): 3547–3551.

U. Del Monte, “Does the Cell Number 109 Still Really Fit One Gram of Tumor Tissue?” Cell Cycle 8, no. 3 (2009): 505–506.

H. G. Welch and W. C. Black, “Using Autopsy Series to Estimate the Disease ‘Reservoir’ for Ductal Carcinoma in Situ of the Breast: How Much More Breast Cancer Can We Find?” Annals of Internal Medicine 127, no. 11 (1997): 1023–1028.

P. H. Zahl, P. C. Gøtzsche, and J. Mæhlen, “Natural History of Breast Cancers Detected in the Swedish Mammography Screening Programme: A Cohort Study,” The Lancet Oncology 12, no. 12 (2011): 1118–1124.

K. D. Miller et al., “Cancer Treatment and Survivorship Statistics,” CA: A Cancer Journal for Clinicians 66 (2016): 271–289.

N. Howlader et al., SEER Cancer Statistics Review, 1975–2012 (Bethesda, MD: National Cancer Institute, 2015), http://seer.cancer.gov/csr/1975_2012.

D. A. Berry et al., “Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer,” New England Journal of Medicine 353 (2005): 1784–1792.

F. Cardoso et al., “70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer,” New England Journal of Medicine 375, no. 8 (2016): 717–729.

R. J. Simes and A. S. Coates, “Patient Preferences for Adjuvant Chemotherapy of Early Breast Cancer: How Much Benefit Is Needed?” JNCI Monographs 2001, no. 30 (2001): 146–152.

“Dose-Dense Chemotherapy Improves Outcomes in Breast Cancer,” Medscape, открыто 9 декабря 2017 года, https://www.medscape.com/viewarticle/889697?nlid=119488_2202.

E. L. Mayer, “Early and Late Long-Term Effects of Adjuvant Chemotherapy,” in American Society of Clinical Oncology Educational Book 2013 (Houston, TX: ASCO University, 2013), 9–14, https://meetinglibrary.asco.org/record/78715/edbook.

I. F. Tannock et al., “Cognitive Impairment Associated with Chemotherapy for Cancer: Report of a Workshop,” Journal of Clinical Oncology 22, no. 11 (2004): 2233–2239.

V. Fuchs-Tarlovsky, “Role of Antioxidants in Cancer Therapy,” Nutrition 29, no. 1 (2013): 15–21.

M. G. Marmot et al., “The Benefits and Harms of Breast Cancer Screening: An Independent Review: A Report Jointly Commissioned by Cancer Research U. K. and the Department of Health (England), October 2012,” British Journal of Cancer 108, no. 11 (2013): 2205–2240.

J. A. van der Hage et al, “Preoperative Chemotherapy in Primary Operable Breast Cancer: Results from the European Organization for Research and Treatment of Cancer Trial,” Journal of Clinical Oncology 19, no. 22 (2001): 4224–4237.